Browse by author
Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer
Lookup NU author(s): Professor Thomas Lennard
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Ifosfamide has single agent activity in advanced breast cancer and may potentiate the activity of doxorubicin. The combination of ifosfamide 5 g/m(2) and doxorubicin 40 mg/m(2) every 3 weeks for 4 cycles was used to treat 77 patients with advanced breast cancer. Fifty three patients had not received prior chemotherapy. All patients had one or more poor prognostic features, including tumor expression of epidermal growth factor receptor in 11/12 tested. The overall response rate was 74% (95% confidence intervals 62%-83%). The median survival was 9.4 months. The principal toxicities were febrile neutropenia and ifosfamide encephalopathy each in 6% of patients. A high percentage of the projected dose intensity was administered. This is a highly active combination with acceptable toxicity in advanced breast cancer, although the long term survival remains poor. Further exploration of ifosfamide in combination chemotherapy for advanced breast cancer is warranted.
Author(s): Millward M, Lind M, Gumbrell L, Robinson A, Lennard TWJ, Cantwell B
Publication type: Article
Publication status: Published
Journal: Breast Cancer Research and Treatment
Year: 1994
Volume: 29
Issue: 3
Pages: 271-277
Print publication date: 01/01/1994
ISSN (print): 0167-6806
ISSN (electronic): 1573-7217
URL: http://dx.doi.org/10.1007/BF00666481
DOI: 10.1007/BF00666481
Altmetrics provided by Altmetric
